Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bolt Biotherapeutics (BOLT) Cash & Equivalents (2020 - 2025)

Bolt Biotherapeutics' Cash & Equivalents history spans 6 years, with the latest figure at $17.8 million for Q3 2025.

  • For Q3 2025, Cash & Equivalents rose 89.55% year-over-year to $17.8 million; the TTM value through Sep 2025 reached $17.8 million, up 89.55%, while the annual FY2024 figure was $7.2 million, 33.35% down from the prior year.
  • Cash & Equivalents for Q3 2025 was $17.8 million at Bolt Biotherapeutics, up from $9.6 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $95.5 million in Q1 2021 and bottomed at $4.3 million in Q1 2024.
  • The 5-year median for Cash & Equivalents is $10.8 million (2023), against an average of $21.2 million.
  • The largest annual shift saw Cash & Equivalents surged 722.12% in 2021 before it crashed 71.27% in 2024.
  • A 5-year view of Cash & Equivalents shows it stood at $27.4 million in 2021, then tumbled by 66.24% to $9.2 million in 2022, then increased by 16.94% to $10.8 million in 2023, then tumbled by 33.35% to $7.2 million in 2024, then skyrocketed by 146.4% to $17.8 million in 2025.
  • Per Business Quant, the three most recent readings for BOLT's Cash & Equivalents are $17.8 million (Q3 2025), $9.6 million (Q2 2025), and $8.4 million (Q1 2025).